CVRx®Barostim™ Heart Failure System Gains MR-Conditional Labeling Approval

CVRx®Barostim™ Heart Failure System Gains MR-Conditional Labeling Approval

CVRx, Inc., developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. FDA approval for magnetic resonance (MR) conditional labeling for its Barostim System.Heart FailureHeart failure is a chronic, progressive condition in...

Latest News

Japanese PMDA Approval for BioFreedom™ Ultra and US FDA Approval for BioFreedom™

Biosensors International Group, Ltd. has announced the Japanese PMDA Approval for BioFreedom™...

read the full article >

Myopia in Childhood: Screens to Blame

Cases of Myopia (near-sightedness) have doubled since the 1960s and will double again by 2050...

read the full article >

Cardiology

Approvals / Clearance

Clinical Studies / Trials

Archimedes Effective in Guiding Sampling of Cancerous Peripheral Lung Lesions

A newly published global multicenter study demonstrates the effectiveness of the Broncus Medical,...

read the full article >

Tibial Neuromodulation for OAB: First Patient Implants

Medtronic plc says the first patient implants in the TITAN 2 pivotal study will evaluate the safety...

read the full article >